Journal article

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial

Abstract:: Importance

Developing effective vaccines against Ebola virus is a global priority

Objective

To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV) and a modified vaccinia Ankara vector vaccine, encoding glycoproteins from Ebola virus, Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein (MVA-BN-Filo).

Design, Setting, and Participants

Single-center, randomized, placebo-controlled, observer-blind, phase 1 ...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Milligan, I., Gibani, M., Sewell, R., Clutterbuck, E., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M., De Rosa, S., Frahm, N., Cohen, K., Shukarev, G., Orzabal, N., van Duijnhoven, W., Truyers, C., Bachmayer, N., Splinter, D., … Snape, M. (2016). Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. Journal of the American Medical Association, 315(15), 1610–1623.

MLA Style

Milligan, I, et al. “Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: a Randomized Clinical Trial.” Journal of the American Medical Association, vol. 315, no. 15, 2016, pp. 1610–23.

Chicago Style

Milligan, I, M Gibani, R Sewell, et al. 2016. “Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: a Randomized Clinical Trial.” Journal of the American Medical Association 315 (15): 1610–23.
Print

Access Document

Files:: Pollard et al, Safety and immunogenicity of novel adenovirus t...

(Preview, Version of record, pdf, 360.3KB, Terms of use)

Publisher copy:: 10.1001/jama.2016.4218

Authors

+ Milligan, I More by this author

Institution:: University of Oxford
Division:: MSD
Role:: Author

+ Gibani, M More by this author

Institution:: University of Oxford
Division:: MSD
Role:: Author

+ Sewell, R More by this author

Institution:: University of Oxford
Division:: MSD
Role:: Author

+ Clutterbuck, E More by this author

Institution:: University of Oxford
Division:: MSD
Role:: Author

+ Campbell, D More by this author

Institution:: University of Oxford
Division:: MSD
Role:: Author

More authors...

+ European Union More from this funder

Grant:: 115854

+ Crucell Holland More from this funder

Publisher:: American Medical Association
Journal:: Journal of the American Medical Association More from this journal
Volume:: 315
Issue:: 15
Pages:: 1610-1623
Publication date:: 2016-04-01
DOI:: 10.1001/jama.2016.4218
EISSN:: 1538-3598
ISSN:: 0098-7484

Language:: English
Pubs id:: pubs:616961
UUID:: uuid:47a586ab-4fb9-4bb1-8184-58968730fab9
Local pid:: pubs:616961
Source identifiers:: 616961
Deposit date:: 2016-04-26
ARK identifier:: ark:/29072/ora_47a586ab4fb94bb1818458968730fab9

Terms of use

Copyright holder:: American Medical Association
Copyright date:: 2016
Notes:: Copyright 2016 American Medical Association. All rights reserved.

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP